Anktiva
Phase 3- Indications
- Bladder cancer, Non-muscle invasive bladder cancer
Company intelligence / Profile preview
NantKwest, Inc.
San Diego, California, USAimmunitybio.com ↗
- Ownership
- Private
- Employees
- ~100
- Development stage
- Phase 3
01
Overview
NantKwest’s off-the-shelf natural killer cell therapies demonstrated safety and early efficacy signals in multiple phase I/II clinical trials for both hematologic cancers and solid tumors. Combination approaches with immunomodulators showed durable responses in some late-stage metastatic cancers.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Cell therapy (natural killer cells)Engineered cell therapies (CAR-NK, haNK, t-haNK)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
ImmunityBioVarious pharmaceutical companies licensed non-clinical use of CD16-bearing aNK lines for antibody testingAdditional collaborations via the NantWorks ecosystem
Beyond the preview
Go deeper on NantKwest, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NantKwest, Inc..